SCYNEXIS (NASDAQ:SCYX) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of SCYNEXIS (NASDAQ:SCYX – Get Rating) in a research note published on Thursday morning. The firm issued a sell rating on the stock.

Separately, Guggenheim assumed coverage on shares of SCYNEXIS in a research note on Tuesday, February 28th. They issued a buy rating and a $8.00 price target for the company.

SCYNEXIS Stock Down 10.2 %

Shares of NASDAQ SCYX opened at $1.15 on Thursday. The company has a debt-to-equity ratio of 2.63, a quick ratio of 7.21 and a current ratio of 7.26. SCYNEXIS has a 12 month low of $1.15 and a 12 month high of $5.15. The firm has a fifty day simple moving average of $1.61 and a two-hundred day simple moving average of $2.03.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Citigroup Inc. bought a new position in shares of SCYNEXIS in the 1st quarter worth about $26,000. State Street Corp grew its position in SCYNEXIS by 9.3% during the 1st quarter. State Street Corp now owns 78,630 shares of the company’s stock valued at $307,000 after purchasing an additional 6,694 shares during the last quarter. Chicago Partners Investment Group LLC grew its position in SCYNEXIS by 20.4% during the 1st quarter. Chicago Partners Investment Group LLC now owns 50,192 shares of the company’s stock valued at $106,000 after purchasing an additional 8,517 shares during the last quarter. Park Avenue Securities LLC purchased a new stake in SCYNEXIS during the 3rd quarter valued at about $34,000. Finally, Dimensional Fund Advisors LP purchased a new stake in SCYNEXIS during the 3rd quarter valued at about $41,000. 49.92% of the stock is currently owned by institutional investors.

SCYNEXIS Company Profile

(Get Rating)

SCYNEXIS, Inc is a biotechnology company engaged in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections.